Nebraska Center for Molecular Target Discovery and Development

项目概要：总体 内布拉斯加州分子靶标发现和开发中心 (CMTDD) 的目标是建立和 扩大内布拉斯加大学医学中心 (UNMC) 的体力和智力资源以及 内布拉斯加大学系统促进方法的识别、验证和开发 操纵与临床重要疾病有关的分子靶标。我们察觉到越来越多的 期刊和资助机构对日益复杂的模型系统和数据集的期望。 获取这些系统和生成高内容数据通常需要大量时间投资 以及对有限的研究资源征税的资金。提升CMTDD研究项目的竞争力 CMTDD 最近投资于第二阶段的领导者 (RPL) 和其他大学教职人员 开发技术以提高研究者研究的复杂性，同时最大限度地降低研究成本 访问。这些技术：单细胞和空间转录组分析、类器官生成和 操作、抑制剂和蛋白水解靶向嵌合体（PROTAC）的合成将被整合为三个 第 2 阶段 CMTDD 核心。这些投资将增强该机构的研究能力，扩大 其教师的翻译能力，促进有前途的新人的培训、指导和职业发展 教师，并有效地推动发现和发展，以改善内布拉斯加州和 国家。第二阶段 RPL 为 CMTDD 带来了广泛的尖端专业知识。有指导并做好准备 访问 CMTDD 支持的核心，我们的 RPL 将成为对社会无价的自给自足的教职人员 UNMC 未来的成功。我们的 2 期 RPL 都对探索基本生物学原理充满热情 细胞稳态的基础，并相信许多疾病可以有效地分类和表征 通过详细的基因组、遗传和分子分析来识别驱动因素和脆弱性 将会出现独特的治疗方法。为了实现这一愿景，CMTDD 将： 1) 维持行政管理 核心和指导计划在最初四年内成功毕业，除了其中一个初始 RPL 之外的所有项目 支持； 2）通过新建立的最先进的单细胞科学核心提高研究能力 空间转录组学、类器官开发以及抑制剂和 PROTAC 合成和验证；和 3) 提供低成本或无成本获取这些技术和试剂，作为增加 研究者研究的影响。

Project Summary: Overall The goal of the Nebraska Center for Molecular Target Discovery and Development (CMTDD) is to establish and expand physical and intellectual resources at the University of Nebraska Medical Center (UNMC) and the University of Nebraska system to catalyze the identification, validation, and development of approaches for manipulation of molecular targets implicated in clinically important diseases. We perceive an increasing expectation by journals and granting agencies for progressively sophisticated model systems and data sets. Acquisition of these systems and generation of high-content data often requires a substantial investment in time and money that taxes limited research resources. To enhance the competitiveness of CMTDD Research Project Leaders (RPLs) and other university faculty members during Phase 2, the CMTDD recently invested in the development of technologies to enhance the sophistication of investigator research while minimizing the cost of access. These technologies: single-cell and spatial transcriptomic analysis, organoid generation and manipulation, and inhibitor and proteolysis-targeting chimera (PROTAC) synthesis will be integrated into three Phase 2 CMTDD cores. These investments will enhance the research capabilities of the institution, expand the translational capacity of its faculty, facilitate the training, mentoring, and career advancement of promising new faculty, and efficiently drive discovery and development for the improvement of human health in Nebraska and the nation. Phase 2 RPLs bring a breadth of cutting-edge expertise to the CMTDD. With mentoring and ready access to CMTDD-supported cores, our RPLs will become self-supporting faculty members invaluable to the future success of UNMC. Our Phase 2 RPLs share both a passion for exploration of the basic biologic principles that underly cell homeostasis and a belief that many diseases can be effectively classified and characterized through detailed genomic, genetic, and molecular analyses that identify drivers and vulnerabilities from which will emerge unique therapeutic approaches. To realize this vision, the CMTDD will: 1) maintain an Administrative Core and mentoring program that successfully graduated all but one of its initial RPLs in the first four years of support; 2) increase research capacity through newly established state-of-the-art scientific cores for single-cell and spatial transcriptomics, organoid development, and inhibitor and PROTAC synthesis and validation; and 3) provide low- or no-cost access to these technologies and reagents as an affordable means for increasing the impact of investigator research.